Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bearish -20

Revenue of Moderna Inc. from 2016 to 2025 (in million U.S. dollars) - Statista

📉 Moderna's total revenue dropped to approximately $2 billion in 2025 due to decreasing demand for its COVID-19 vaccine, Spikevax.

💊 The company remains a clinical-stage biotech firm with no current commercial revenue from potential drug candidates awaiting regulatory approval.

🔬 Annual research and development costs continue to rise as Moderna invests significantly in advancing its mRNA therapeutics pipeline.

🦠 Moderna's vaccine, mRNA-1273, was approved for widespread use in late 2020 after successfully completing all necessary clinical phases.

🤝 The company developed its initial COVID-19 vaccine in partnership with the National Institutes of Health and CEPI.

Bullish Signals
  • Moderna is a pioneering clinical-stage biotech company that successfully developed and manufactured an mRNA vaccine in only 25 days.
  • The company's vaccine, mRNA-1273, was the second approved for widespread use globally after receiving full regulatory clearance in late 2020.
  • Moderna maintains strategic partnerships with major organizations like the NIH and CEPI to advance epidemic preparedness and vaccine development.
Risk Factors
  • Total revenue decreased significantly in 2025 compared to prior years, driven by a sharp decline in demand for the COVID-19 vaccine.
  • The company has not yet generated any commercial revenue from its pipeline of potential drugs, relying entirely on vaccine sales and collaborations.
  • Annual research and development costs continue to grow, placing ongoing financial pressure on the organization as it seeks new approvals.
Full Analysis
Moderna Inc. reported total worldwide revenues of approximately two billion U.S. dollars in 2025, marking a significant decline from previous years. This decrease is primarily attributed to waning demand for its COVID-19 vaccine, Spikevax, which was the company's dominant revenue driver during the pandemic. As a clinical-stage biotechnology firm, Moderna continues to pioneer messenger RNA therapeutics and vaccines. However, the company has not yet generated commercial revenue from potential drug candidates, as it remains dependent on completing clinical development and securing regulatory approval for new medicines before sales can commence. The article highlights that annual research and development costs continue to grow as the company invests heavily in its pipeline. Moderna was a pioneer in developing mRNA-1273, which received widespread approval in late 2020 following rapid design and manufacturing efforts in partnership with the NIH and CEPI.